Paintable Chemotherapy Could Shrink Skin Tumors
Skin acts as the first line of defense against pathogens and other harmful material from outside the body. Yet this barrier also excludes some beneficial drugs that could treat skin diseases. Now, researchers have taken the first steps in developing a chemotherapy for melanoma that can be "painted" directly on the skin, rather than injected or taken orally. They report their results in ACS Nano.
According to the Skin Cancer Foundation, melanoma is the deadliest form of cancer because of its tendency to spread, or metastasize, from the skin to other parts of the body. Common treatments include surgery, radiation therapy and intravenous chemotherapy, but these can cause pain or unpleasant side effects. If scientists could find a way to administer chemotherapy through the skin, they could target the treatment directly to the tumor site and possibly avoid side effects. Bingfang He, Ran Mo and colleagues wanted to develop a gel that patients themselves could apply to a skin tumor. But first they had to figure out how to get the therapy to penetrate deep within the skin.
For this purpose, the researchers assembled nanoparticles called "transfersomes," which consist of a phospholipid bilayer and surfactants that encapsulate drugs or other molecules --- in this case, the chemotherapy drug paclitaxel. The surfactants made the particles more deformable so that they could better infiltrate the skin; these compounds also affected the lipid matrix of the skin to help the particles more easily pass. The researchers added a peptide to the surface of the transfersome to further help the particle penetrate the skin, as well as enter tumor cells. To increase the time that the transfersomes persisted on skin, the researchers embedded the nanoparticles into a hydrogel. Then, they painted the gel on tumors of melanoma-bearing mice once a day, in combination with intravenous administration of paclitaxel every other day. After 12 days, the tumors of these mice were about half the size of tumors in mice treated with intravenous paclitaxel alone, suggesting that the transfersome gel helped slow tumor growth.
This article has been republished from materials provided by American Chemical Society. Note: material may have been edited for length and content. For further information, please contact the cited source.
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE